Name | Value |
---|---|
ABBREVIATION | ESBL |
NAME | Extended-spectrum beta-lactamase |
DIVISION |
|
DESCRIPTION | Extended-Spectrum Beta-Lactamases (ESBLs) are enzymes that mediate Standards Institute (CLSI) testing schema should be used. If an isolate is confirmed as an ESBL-producer by the CLSI-recommended phenotypic confirmatory test procedure, then all penicillins, cephalosporins and aztreonams should be reported as resistant. Cephamycins should be reported according to their routine test results. NOTE: Adding Extended-Spectrum Beta Lactamase to the MDRO Tools Lab Parameter Setup is optional. The purpose of adding pathogens containing this form of antimicrobial resistance to the parameter set-up is to identify a patient's current or prior history of ESBL based on laboratory resistance to extended-spectrum (third generation) cephalosporins (e.g., reporting and the time frames that are entered to search for the patient's status. This information can optionally be displayed on the Isolation Report. If you would like to incorporate ESBL into the Isolation report, the result must occur as a retrievable result as a "bacterial etiology" or in the "BACT RPT REMARK" field. It is appropriate to used Canned Comments versus Free Text to retrieve results. If free-text is used, it is likely the report will not display accurate information. Any results contained in the "Comments" section will not allow incorporation of ESBL into the MDRO Program Tools software Isolation Report format. ceftazidime, cefotaxime, and ceftriaxone) and monobactams (e.g, aztreonam) but do not affect cephamycins (e.g., cefoxitin and cefotetan) or carbapenems (e.g., imipenem or meropenem). ESBLs can be difficult to detect because they have different levels of activity against various cephalosporins. It is critical to test the appropriate antimicrobial agent. An appropriate Committee on Laboratory |